Farewell to Chris Richardson

Chris Richardson joined the lab as a Postdoctoral Fellow in July 2014 and made huge advances in human gene editing. He developed new ways to improve NHEJ and HDR, plus discovered out that genome editing in human cells works via the Fanconi Anemia Pathway. Three major first author papers in three years – not bad! Chris will be joining Spotlight Therapeutics as a Group Leader, and may have some additional career news to share soon. We wish you success in all your future endeavors!

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest News

October 22, 2026

New study reveals how PARP can limit prime editing-mediated insertions-published in THE CRISPR JOURNAL

Prime editing enables precise modifications to DNA without introducing double-strand breaks, offering exciting opportunities for genome engineering....

October 15, 2026

CRISPR IN CLINICAL ONCOLOGY: FROM RESEARCH TO CANCER DIAGNOSTICS AND THERAPIES – PUBLISHED IN NATURE REVIEWS CLINICAL ONCOLOGY

CRISPR technologies have transformed biomedical research, opening new possibilities for understanding, diagnosing, and treating cancer. But how close...

October 15, 2026

Choosing the right tool for precise genome editing – published in Nature Reviews Molecular Cell Biology

The genome-editing toolbox is rapidly expanding, offering increasingly diverse ways to make precise changes to DNA. But with so many emerging technologies,...

News Archive